Schonfeld Strategic Advisors LLC Grows Position in Hologic, Inc. (NASDAQ:HOLX)

Schonfeld Strategic Advisors LLC lifted its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 48.9% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 27,220 shares of the medical equipment provider's stock after acquiring an additional 8,945 shares during the period. Schonfeld Strategic Advisors LLC's holdings in Hologic were worth $1,962,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of HOLX. Benson Investment Management Company Inc. bought a new position in shares of Hologic in the fourth quarter worth about $4,832,000. Principal Financial Group Inc. lifted its holdings in shares of Hologic by 0.6% in the fourth quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider's stock worth $19,547,000 after acquiring an additional 1,606 shares during the last quarter. Clean Yield Group lifted its holdings in shares of Hologic by 18.9% in the fourth quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider's stock worth $3,291,000 after acquiring an additional 7,266 shares during the last quarter. Nordea Investment Management AB lifted its holdings in shares of Hologic by 32.7% in the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider's stock worth $159,911,000 after acquiring an additional 544,889 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of Hologic by 44.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 63,744 shares of the medical equipment provider's stock worth $4,595,000 after acquiring an additional 19,688 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HOLX has been the subject of a number of research reports. Argus cut shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Leerink Partnrs lowered shares of Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. Evercore ISI dropped their price objective on shares of Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a report on Friday, May 2nd. Citigroup dropped their price objective on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Finally, William Blair reiterated an "outperform" rating on shares of Hologic in a report on Thursday, February 6th. Twelve equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $78.58.

Insider Transactions at Hologic

In other news, Director Martin D. Madaus bought 5,445 shares of the business's stock in a transaction on Wednesday, May 7th. The stock was acquired at an average price of $55.24 per share, with a total value of $300,781.80. Following the completion of the purchase, the director now directly owns 5,445 shares in the company, valued at $300,781.80. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 1.88% of the stock is owned by insiders.

Hologic Stock Performance

Hologic stock traded up $0.56 during midday trading on Friday, reaching $56.74. The stock had a trading volume of 3,258,934 shares, compared to its average volume of 2,092,764. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.67. The firm's 50-day moving average price is $59.43 and its 200 day moving average price is $68.17. The firm has a market capitalization of $12.73 billion, a PE ratio of 17.90, a P/E/G ratio of 2.14 and a beta of 0.54. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same quarter in the previous year, the firm earned $1.03 EPS. The company's quarterly revenue was down 1.2% compared to the same quarter last year. As a group, research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.